Axcelis (ACLS) Q1 2026 Earnings Call Transcript

Axcelis reported first-quarter revenue of $199 million and EPS of $0.72, with the results held back by a one-time $5 million customer settlement that cut gross margin by about 70 bps and EPS by $0.09. CS&I revenue grew more than 30% year over year, bookings were $128 million, backlog was $453 million, and the company launched its Purion H6 high-current system while securing a new customer win in China. Management kept full-year 2026 revenue guidance flat year over year but expects stronger memory and silicon carbide demand to drive a second-half-weighted recovery and a return to growth in 2027.

Analysis

The signal is not the headline quarter; it is the inflection in mix quality beneath a flat top line. Memory and CS&I are doing the heavy lifting, which matters because both tend to carry better margin and indicate installed-base monetization rather than pure new-tool cyclicality. That creates a more durable earnings floor heading into 2H, especially if utilization keeps rising and upgrade/spares attach continues to compound.

The bigger second-order takeaway is that Axcelis is becoming more levered to two secular demand pools that are still early: AI-related DRAM/HBM and power architecture for AI infrastructure. The company’s comments suggest data-center exposure is not a near-term revenue driver, but it is a call option on future implant demand as the power tree shifts from grid-to-rack. If that architecture shift proves real, the market is likely underestimating the duration of the silicon-carbide recovery and the optionality embedded in the merger.

Near term, the main risk is that the market extrapolates too much from one quarter of firmer bookings while end markets outside memory remain in digestion. This is a classic semiconductor setup where revenue can look stable while the order book is quietly improving underneath, but that can reverse quickly if China demand cools or if memory capex pauses after initial HBM buildouts. The merger adds a layer of event risk: if approval slips, the stock may lose some of the strategic halo even if fundamentals hold.

Consensus may be missing that the flat-2026 guide is likely conservative, not because management is sandbagging on revenue, but because it has limited visibility into when power and mature segments reaccelerate. That means the stock’s upside is less about this year’s EPS and more about multiple expansion on 2027 growth re-acceleration plus merger completion. In that framework, current numbers matter mainly insofar as they confirm the trough is behind them.

Key Decisions for Investors

• Go long ACLS on pullbacks over the next 2-6 weeks; use the flat-2026 guide as a base case, with upside to 2027 growth/multiple re-rating if bookings stay near 1.0 book-to-bill.
• Buy ACLS Jan-2027 calls or call spreads to express the 2027 recovery setup; risk/reward favors convex exposure because the stock can rerate before revenue inflects.
• Pair trade: long ACLS / short a more mature semi-cap name with weaker memory exposure over 3-6 months; ACLS has better embedded operating leverage from CS&I and AI-memory mix.
• If merger approval from China remains unresolved into the next quarter, hedge ACLS longs with short-dated puts or collars; event slippage is the clearest catalyst for multiple compression.
• Monitor memory order momentum and general mature bookings as the key swing indicators; if either rolls over for two consecutive quarters, reduce exposure quickly because the thesis is cyclical, not structural, at this stage.